Project Highlights
View AllIn the News
View All
Illumina launches BioInsight Platform, its first unified software environment to help accelerate genomic and multiomic breakthroughs
10/14/2026 — The new platform brings together advanced analysis, purpose-built AI, and curated biological data so researchers can move more quickly from complex genomic and multiomic data to actionable insight. Included in the new platform, latest DRAGEN update expands access to Illumina's award-winning secondary analysis across supported cloud and standard computing environment
NeuroVoices: Kamalini Galvelis, MS, on Why Diverse Cohorts Matter in Replicating a GBA1 Intronic Risk Variant
10/07/2026 — At the 2026 International Congress of Parkinson's Disease and Movement Disorders, held October 4-8 in Seoul, South Korea, investigators from the Parkinson's Foundation presented what they describe as the first large-scale replication of a GBA1 risk signal associated with African ancestry.1 The variant, rs3115534-G, sits in intron 8 of GBA1 and disrupts splicing, lowering glucocerebrosidase activity.2 It was first identified in a genome-wide meta-analysis of nearly 198,000 people of African and African admixed ancestry, where it was linked to greater odds of Parkinson disease (PD) and a younger age at onset.
Exploring Genetic Differences in Parkinson’s Disease by Ancestry
08/04/2026 — A landmark international study has found that the genetic drivers of Parkinson’s disease can vary dramatically between populations, underscoring the need to include people of various ancestries in genetic research and clinical trials.
Turning on the data tap at GP2
07/22/2026 — A new paper in the journal JAMA Neurology presents a progress report from the Global Parkinson Genetics Program, or “GP2.” That’s a world-wide collaboration to study the genetics not only Parkinson’s disease, but also dementia with Lewy bodies, multiple system atrophy, corticobasal degeneration — and PSP.
The Components of GP2’s 12th Data Release
06/30/2026 — In July 2026, GP2 announced the 12th data release on the Terra and the Verily® Workbench platforms in collaboration with AMP® PDRD. This release includes 21,156 additional genotyped participants and 25,046 additional whole genome sequencing (WGS) participants.
